This Skeptical Sunday, Jessica Wynn explains how dialysis became a $50B industry where under 40% of patients survive five painful years of dependence.
Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we’re joined by writer and researcher Jessica Wynn!
Dialysis is a life-sustaining external filtration system for the roughly 800,000 Americans in kidney failure — but it's grueling. Most patients endure three to five hours per session, three times a week, indefinitely, and fewer than 40% survive beyond five years.
The financial structure is staggering. Dialysis is a $50 billion-a-year US industry, with Medicare spending about $36 billion annually — roughly 7% of its entire budget for under 1% of the population. Two companies, DaVita and Fresenius, control about 70% of all clinics.
The system rewards permanence over cure. Since 1972, Medicare has covered kidney failure for everyone regardless of age, creating guaranteed, indefinite revenue. Transplants and home dialysis are cheaper and better for patients, yet under-incentivized because they cost providers customers.
The human and safety toll is severe. Infections cause 36% of dialysis deaths, sepsis mortality runs 100 to 300 times higher than average, and understaffing worsens outcomes. Many patients lose their jobs, mobility, and social lives — some choose to stop treatment entirely.
The hopeful part: much kidney disease is preventable or delayable, and you have real power here. Manage diabetes and hypertension aggressively, get your kidneys checked with a simple blood and urine test, and see a nephrologist early — catching it sooner can dramatically slow progression.
Podden och tillhörande omslagsbild på den här sidan tillhör
Jordan Harbinger. Innehållet i podden är skapat av Jordan Harbinger och inte av,
eller tillsammans med, Poddtoppen.
